Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?

Marc E Lippman

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Standard approaches to the systemic management of breast cancer have probably reached a plateau. Endocrine therapy leads to responses in only 1/3 of patients, probably even less if no clinical preselection is applied, and the median benefit probably does not exceed one year. Although three-drug chemotherapeutic combinations yield responses in 55-65% of patients, the median duration of response is at best only 10 months, and addition of more drugs does not seem to offer much additional benefit. Although combining these approaches seems attractive initially, the theoretical improvement would be modest even if the effects were additive, and in fact the endocrine component may well perturb the cell cycle kinetics to reduce sensitivity to the cytotoxic component so that results would be less than additive. Clinical trials of combined chemoendocrine regimens have tended to evaluate only the initial response rate, whereas a valid comparison must consider the total response duration and survival given either combined or the usual sequential approaches. Combining endocrine and cytotoxic chemotherapies may have a greater effect when a more rational means for their amalgamation is employed. Early trials using endocrine manipulation to synchronize cell sensitivity to cytotoxic treatment have been promising. Increasing attention needs to be directed towards more innovative trial design which is respectful of the biological realities of cancer.

Original languageEnglish
Pages (from-to)117-127
Number of pages11
JournalBreast Cancer Research and Treatment
Volume3
Issue number2
DOIs
StatePublished - Jun 1 1983
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Drug Combinations
Cell Cycle
Clinical Trials
Survival
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • chemotherapy
  • combined chemoendocrine therapy
  • endocrine therapy
  • systemic management of breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efforts to combine endocrine and chemotherapy in the management of breast cancer : Do two and two equal three? / Lippman, Marc E.

In: Breast Cancer Research and Treatment, Vol. 3, No. 2, 01.06.1983, p. 117-127.

Research output: Contribution to journalArticle

@article{1e6fd33e9d9e49f3bf2c1737f1073c6d,
title = "Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?",
abstract = "Standard approaches to the systemic management of breast cancer have probably reached a plateau. Endocrine therapy leads to responses in only 1/3 of patients, probably even less if no clinical preselection is applied, and the median benefit probably does not exceed one year. Although three-drug chemotherapeutic combinations yield responses in 55-65{\%} of patients, the median duration of response is at best only 10 months, and addition of more drugs does not seem to offer much additional benefit. Although combining these approaches seems attractive initially, the theoretical improvement would be modest even if the effects were additive, and in fact the endocrine component may well perturb the cell cycle kinetics to reduce sensitivity to the cytotoxic component so that results would be less than additive. Clinical trials of combined chemoendocrine regimens have tended to evaluate only the initial response rate, whereas a valid comparison must consider the total response duration and survival given either combined or the usual sequential approaches. Combining endocrine and cytotoxic chemotherapies may have a greater effect when a more rational means for their amalgamation is employed. Early trials using endocrine manipulation to synchronize cell sensitivity to cytotoxic treatment have been promising. Increasing attention needs to be directed towards more innovative trial design which is respectful of the biological realities of cancer.",
keywords = "chemotherapy, combined chemoendocrine therapy, endocrine therapy, systemic management of breast cancer",
author = "Lippman, {Marc E}",
year = "1983",
month = "6",
day = "1",
doi = "10.1007/BF01803554",
language = "English",
volume = "3",
pages = "117--127",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Efforts to combine endocrine and chemotherapy in the management of breast cancer

T2 - Do two and two equal three?

AU - Lippman, Marc E

PY - 1983/6/1

Y1 - 1983/6/1

N2 - Standard approaches to the systemic management of breast cancer have probably reached a plateau. Endocrine therapy leads to responses in only 1/3 of patients, probably even less if no clinical preselection is applied, and the median benefit probably does not exceed one year. Although three-drug chemotherapeutic combinations yield responses in 55-65% of patients, the median duration of response is at best only 10 months, and addition of more drugs does not seem to offer much additional benefit. Although combining these approaches seems attractive initially, the theoretical improvement would be modest even if the effects were additive, and in fact the endocrine component may well perturb the cell cycle kinetics to reduce sensitivity to the cytotoxic component so that results would be less than additive. Clinical trials of combined chemoendocrine regimens have tended to evaluate only the initial response rate, whereas a valid comparison must consider the total response duration and survival given either combined or the usual sequential approaches. Combining endocrine and cytotoxic chemotherapies may have a greater effect when a more rational means for their amalgamation is employed. Early trials using endocrine manipulation to synchronize cell sensitivity to cytotoxic treatment have been promising. Increasing attention needs to be directed towards more innovative trial design which is respectful of the biological realities of cancer.

AB - Standard approaches to the systemic management of breast cancer have probably reached a plateau. Endocrine therapy leads to responses in only 1/3 of patients, probably even less if no clinical preselection is applied, and the median benefit probably does not exceed one year. Although three-drug chemotherapeutic combinations yield responses in 55-65% of patients, the median duration of response is at best only 10 months, and addition of more drugs does not seem to offer much additional benefit. Although combining these approaches seems attractive initially, the theoretical improvement would be modest even if the effects were additive, and in fact the endocrine component may well perturb the cell cycle kinetics to reduce sensitivity to the cytotoxic component so that results would be less than additive. Clinical trials of combined chemoendocrine regimens have tended to evaluate only the initial response rate, whereas a valid comparison must consider the total response duration and survival given either combined or the usual sequential approaches. Combining endocrine and cytotoxic chemotherapies may have a greater effect when a more rational means for their amalgamation is employed. Early trials using endocrine manipulation to synchronize cell sensitivity to cytotoxic treatment have been promising. Increasing attention needs to be directed towards more innovative trial design which is respectful of the biological realities of cancer.

KW - chemotherapy

KW - combined chemoendocrine therapy

KW - endocrine therapy

KW - systemic management of breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0020959935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020959935&partnerID=8YFLogxK

U2 - 10.1007/BF01803554

DO - 10.1007/BF01803554

M3 - Article

C2 - 6351947

AN - SCOPUS:0020959935

VL - 3

SP - 117

EP - 127

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -